Bayer begins enrollment for Phase III trial of florbetaben

11/30/2009 | Reuters

Bayer initiated enrollment for a Phase III trial of PET imaging agent florbetaben, which zeroes in on beta-amyloid plaques associated with Alzheimer's disease. The study will have about 400 participants. A Phase II study showed that the agent can help diagnose the disease in eight of 10 cases.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
In house Compliance Officer
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC